RESUMEN
<p><b>OBJECTIVE</b>To evaluate the effects of combined treatment of hormone therapy with strontium-89 for pain from bone metastases in patients with prostate cancer.</p><p><b>METHODS</b>Sixteen patients with metastasis prostate cancer received hormone therapy with strontium-89 chloride (89Sr), and 4 of them received radiotherapy.</p><p><b>RESULTS</b>The pain was relieved. Relief occurred in 75.6% of the patients for 3 months, 80.5% for 6 months and 63.4% for 9 months.</p><p><b>CONCLUSION</b>Hormone therapy enhances the effect of 89Sr without obvious toxicity. The combined treatment not only significantly raises pain palliation, prolongs pain-free survival, but improves the patients life quality.</p>
Asunto(s)
Anciano , Anciano de 80 o más Años , Humanos , Masculino , Persona de Mediana Edad , Antagonistas de Andrógenos , Usos Terapéuticos , Neoplasias Óseas , Terapéutica , Terapia Combinada , Dolor Intratable , Terapéutica , Neoplasias de la Próstata , Terapéutica , Estroncio , Usos TerapéuticosRESUMEN
<p><b>OBJECTIVE</b>To explore the possible relationship between erectile dysfunction (ED) and benign prostate hyperplasia (BPH) in men, and to assess the positive effect of Sildenafil on the lower urinary tract symptoms (LUTS) from BPH while treating ED.</p><p><b>METHODS</b>Thirty-two patients with ED and BPH were offered oral Sildenafil and reviewed before and six months after the administration of Sildenafil by the International Index of Erectile Function-5 (IIEF-5) and the International Prostate Symptom Score (IPSS) questionnaires. Scores were tested by chi-square.</p><p><b>RESULTS</b>IIEF-5 scores were increased by 42.36% and IPSS scores declined by 20.14%, with statistical significance (P < 0.01).</p><p><b>CONCLUSION</b>Treatment of ED with Sildenafil appears to improve urinary symptom scores. A lower IPSS at baseline seems to predict a better response to Sildenafil therapy for ED.</p>